A single dose of psilocybin provided months of relief from chronic suicidal thoughts, highlighting a potential therapeutic application for this psychedelic compound in psychiatry.
This meta-analysis quantifies initiation and discontinuation rates for oral and depot naltrexone in opioid use disorder, finding that supervised administration significantly reduces early discontinuation of oral formulations.
A meta-analysis suggests that clinical trials for alcohol use disorder medications lasting 12 weeks or less may be as effective as longer trials, challenging current FDA recommendations for six-month study durations.
Community-level increases in buprenorphine treatment initiation and long-term retention are significantly associated with reduced opioid overdose mortality rates.
Higher antipsychotic doses negatively correlate with cognitive improvements from tDCS in schizophrenia, suggesting that minimizing pharmacological burden may optimize neuromodulation efficacy.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Jan 07 – Jun 14)
- Consider pre-treatment ACKR1 genetic testing for patients prescribed clozapine to mitigate the risk of severe neutropenia.
- Minimize antipsychotic doses when combining them with tDCS in schizophrenia, as higher doses negatively correlate with cognitive improvements from neuromodulation.
- Advise supervised administration for oral naltrexone in opioid use disorder to significantly reduce early discontinuation rates compared to unsupervised use.
- Note that community-level increases in buprenorphine initiation and retention are associated with reduced opioid overdose mortality, supporting broader access strategies.
- Evaluate the potential of a single psilocybin dose for providing sustained relief from chronic suicidal thoughts in appropriate clinical contexts.
- Reassess expectations for alcohol use disorder medication trials, as evidence suggests durations of 12 weeks or less may be sufficient for efficacy.
Pharmacogenomics 1
This article advocates for pre-treatment ACKR1 genetic testing to mitigate the risk of severe neutropenia in patients prescribed clozapine, highlighting a pharmacogenomic approach to prescribing safety.